SCHEMBL12401774

SCHEMBL12401774

CCc1ccc(Oc2ccccc2C(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.43
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
RXRG P48443 1/20 0.43
EZH2 Q15910 1/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RIPK1 Q13546 1/20 0.41
P2RY1 P47900 2/20 0.40
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
HSP90AB1 P08238 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12806556 0.85 LTA4H (0.51) FFAR1RXRARXRBRXRGALDH1A1
SCHEMBL12239020 0.85 ST14 (0.47) FFAR1RXRARXRBRXRGEZH2
SCHEMBL278540 0.81 RIPK1 (0.53) FFAR1RXRARXRBRXRGEZH2
SCHEMBL12862911 0.80 L3MBTL1 (0.45) FFAR1EZH2ALDH1A1MAPK1HTT
SCHEMBL12412410 0.80 ALDH1A1 (0.55) FFAR1EZH2ALDH1A1MAPK1HTT
SCHEMBL28367828 0.79 ALDH1A1 (0.53) FFAR1EZH2ALDH1A1MAPK1HTT
SCHEMBL7041285 0.78 PTGDR2 (0.38) ALDH1A1SLC6A2SLC6A4SLC6A3KDM4E
SCHEMBL7041987 0.77 CYP2A6 (0.34) ALDH1A1L3MBTL1HSP90AB1
SCHEMBL30500977 0.77 ALDH1A1 (0.48) RXRARXRBRXRGALDH1A1HTT
SCHEMBL127278 0.77 ALDH1A1 (0.48) RXRARXRBRXRGALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-7985762-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 FFAR1 4665/4885RXRA 4746/4885RXRB 4701/4885
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 FFAR1 4679/4885RXRA 4801/4885RXRB 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.